which determines the outcome of the immunological response. While the phenotype and function of macrophages that mediate the induction of transplantation tolerance has recently been reported, 5 their developmental requirements remain poorly understood.
Monocytes differentiate into classically (Ly6C hi /M1) or alternatively (Ly6C lo /M2) activated macrophages according to the local environment. 7, 8 Inflammatory Ly6C hi monocytes are rapidly recruited to inflamed tissues and become alternatively activated Ly6C lo A B C D E F I G U R E 1 Neutrophil derived CSF1 mediates macrophage polarization. (A and B) CSF1 expression in the allografts. Heart allografts of CD40L mAb treated mice were isolated and single cells suspensions were made. CSF1 expression in distinct flow sorted cell subsets was investigated by qPCR. Results represent mean ± SEM of three independent experiments (unpaired Mann-Whitney and Kruskal-Walis with Dunn's multiple comparison test; *P ≤ .5). (C) CSF1 expression in the allografts of S100A8 Cre CSF1 fl deficient recipient mice. Heart allografts of wt and S100A8 Cre CSF1 fl recipients treated with CD40L mAb were analyzed for CSF1 expression by qPCR. Results represent mean ± SEM of three independent experiments (unpaired Mann-Whitney test; *P ≤ .5). (D) Representative and quantitative flow cytometry results of graft infiltrating myeloid subsets from anti-CD40L mAb treated wt and S100A8 Cre CSF1 fl recipients at day 5 post-transplantation. Results represent mean ± SEM (n = 4 mice per group of three independent experiments; unpaired Mann-Whitney test; *P ≤ .5). (E) Graft survival of tolerized wt versus S100A8
Cre CSF1 fl recipients. Tolerized S100A8 Cre CSF1 fl recipient mice rejected their allografts despite anti-CD40L mAb treatment.
A third group of tolerized S100A8 Cre CSF1 fl recipients received 2 × 10 5 U of recombinant CSF1 i.v. on the day of transplantation and on days 1-5 post-transplantation. Non-tolerized S100A8 Cre CSF1 fl recipients treated with 2 × 10 5 U of recombinant CSF1 were used as controls. Graft survival was assessed with Kaplan-Meier analysis (MST 18 ± 8 days; **P ≤ .01; n = 5 mice per group) macrophages once the inciting inflammatory stimulus has been resolved. 9 In organ transplantation, inflammatory Ly6C hi monocytes infiltrate the allograft early after transplantation and differentiate into suppressive Ly6C lo macrophages following costimulatory blockade. 5 Therefore, the signals that dictate macrophage polarization towards alternatively activated Ly6C lo /M2 control immunological tolerance. 10, 11 Macrophage polarization into suppressive Ly6C lo macrophages is mediated by cytokines and growth factors. 12, 13 In this respect, the colony-stimulating factor 1 (CSF1) has been demonstrated to control macrophage polarization. 14 CSF1 also controls the function of macrophages and several reports have documented suppressive function of CSF1 differentiated macrophages in mixed lymphocyte reactions. [15] [16] [17] This suggests that the local production of CSF1 controls both the differentiation and immune regulatory function macrophages.
Here, we investigated the mechanistic insights of CSF1 on macrophage differentiation and function and we demonstrate that CSF1 producing 
| EXPERIMENTAL PROCEDURES

| Mice
BALB/c and C57BL/6 mice eight weeks of age were purchased from The Jackson Laboratory (Bar Harbor, ME). The C57BL/6 mKO2-hCdt1 (30/120) and mAG-hGem(1/110) transgenic mice were from D. Atsushi Miyawaki (RIKEN, Brain Science Institute, Hirosawa, Saitama, Japan). 18 The CSF1flox mice have been previously described. 19 All experiments were performed with age-and sex-matched mice in accordance with Institutional Animal
Care and Utilization Committee-approved protocols.
| Vascularized heart transplantation
BALB/c hearts were transplanted as fully vascularized heterotopic grafts into C57BL/6 mice as previously described. 20 Recipient mice were treated with 250 μg anti-CD40L mAb (clone MR1, BioXcell, West Lebanon, NH) for tolerance induction on days 0, 2, and 4 as previously described. 21 Graft function was monitored every other day by abdominal palpation. Untreated control mice received hamster IgG in PBS. Rejection was defined as complete cessation of a palpable beat and confirmed by direct visualization at laparotomy.
| Isolation of graft infiltrating leukocytes (GIL)
Mouse hearts were rinsed in situ with HBSS with 1% heparin. Explanted hearts were cut into small pieces and digested for 40 minutes at 37°C
with 400 U/ml collagenase IV (Sigma-Aldrich), 10 mM HEPES (Corning Cellgro, Manassas, VA), and 0.01% DNase I (MP Biomedicals) in HBSS (Cellgro). Digested suspensions were passed through a nylon mesh and centrifuged, and the cell pellet was resuspended in 5 ml 45.5%
Nycodenz solution (Sigma-Aldrich). Complete DMEM (3 ml) was added to the top of the Nycodenz, and gradient centrifugation was performed (1700 g for 15 minutes at 4°C). The cells at the interface were recovered, washed with complete DMEM, stained, and analyzed by flow cytometry (BD LSR-II; BD Biosciences, San Jose, CA).
| Flow cytometry and cell sorting
Fluorochrome-conjugated mAbs specific to mouse CSF-1R (clone 
| Immunofluorescence microscopy
Transplanted hearts were harvested, subdivided, frozen directly in OCT (Fisher, Waltham, MA), and stored at −80°C in preparation for immunological studies. Sections of 8 μm were cut using a Leica 1900CM cryomicrotome, fixed, and mounted with Gel/Mount (Biomeda, Foster City, CA) on polylysine-coated slides. Anti-Ki67 (AbD02531) and CD169 (clone 3D6.112)
were purchased from AbD Serotec (Hercules, CA). All slides were mounted with Vectashield (Vector Laboratories, Burlingame, CA) to preserve fluorescence. Images were acquired with a Leica DMRA2 fluorescence microscope (Wetzlar, Buffalo Grove, IL) and a digital Hamamatsu charge-coupled device camera. Separate green, red, and blue images were collected and analyzed with Openlab software (Improvision, Coventry, England). Expression Console were background corrected, normalized, and summarized using Robust Multichip Average. The summary expression scores were computed at the transcript meta-probeset level using annotation files supplied by the manufacturer. The data was imported into R. Since these arrays were run in different batches, the gene expression was batch corrected with Combat. Gene expression was filtered based on IQR (0.25) filter using genefilter package. The log2 normalized and filtered data (adjusted P < .05) was used for further analysis (GEO accession number GSE68648).
| Microarray
| Quantitative RT-PCR
Total RNA was extracted from purified cells with RNeasy Plus Micro Kit (Qiagen, Hilden, Germany). Reverse transcription was carried out using the Omniscript reverse-transcription system (Qiagen) and random primers. Quantitative PCR was performed with the LightCycler system (Roche, Basel, Switzerland) and the SYBR Green PCR kit (Qiagen). All experiments were done in triplicate at least three separate times, and expression of specific genes was normalized and expressed as percentage relative to housekeeping genes or RNA fold expression according to the ddCT method.
| Bone marrow-derived monocyte cultures
Bone marrow Ly6C hi monocytes were FACS sorted from the mice femur and plated in 96-U-botton well plate at 5 × 10 4 cell/well in RPMI-1640 w/L-Glutamine medium (Corning Cellgro) containing 10%
heat-inactivated FCS (Biochrom, Berlin, Germany), 1% penicillin/streptavidin (Corning Cellgro). Bone marrow Ly6C hi monocytes were then cultured for 72 hours in the presence of recombinant murine CSF1 at 10 ng/ml (Peprotech, Rocky Hill, NJ) or simvastatin loaded HDL nanoparticles (S-HDL) at 10 μM.
| In vitro suppression assay
Spleens of C57BL/6 mice were gently dissociated into single-cell suspensions, and red blood cells were removed using hypotonic ACK lysis buffer. Splenocytes were either stained with anti-CD8 mAb, followed 
| In vivo treatment
Human recombinant CSF1 (Peprotech) wan injected i.v. at 2 × 10 5 U/ mice on days 0-5 relative to transplantation.
| Nanoparticles synthesis
Our targeted approach delivers the drug simvastatin using a synthetic high-density lipoprotein (HDL) nanoparticle. These nanoparticles were synthesized using a lipid film hydration method.
Phospholipids and simvastatin were dissolved in methanol/chloroform. After evaporating the solvents, human ApoA1 in PBS was added to hydrate the lipid film. This resulting solution was sonicated to form small simvastatin loaded HDL nanoparticles (S-HDL).
The animals received 3 intravenous tail injections of S-HDL at 60 mg/kg on the day of transplantation as well as days 2 and 5 post-transplantation.
| Statistics
Differences between graft survival rates were assessed by KaplanMeier survival analysis with Prism software. Unpaired Mann-Whitney test was used when comparing two groups. Kruskal-Wallis with Dunn's multiple comparison test was used for comparisons among multiple groups. Statistical significance is expressed as follows:
*P ≤ .05, **P ≤ .01, NS not significant.
| RESULTS
| Neutrophil derived CSF1 mediates macrophage polarization
Suppressive Ly6C lo macrophages expressing the macrophage colonystimulating factor 1 receptor (CSF-1R, MCSFR, or CD115) mediate the induction of indefinite allograft survival. Figure 1E ). This demonstrates that CSF1 producing neutrophils mediate the development of suppressive Ly6C lo macrophages that promote the induction of indefinite allograft survival.
| Suppressive function of polarized macrophages depends on cell proliferation
Based on the CSF1 requirement for tolerance induction and previous work by others linking CSF1 to cell cycle progression, 24, 25 we tested relationship between cell cycle progression of suppressive . 18 We transplanted BALB/c hearts into anti-CD40L mAb-treated C57BL6 Fucci transgenic (mKO2/mAG) recipient mice, harvested the allografts at day 5 posttransplantation, and analyzed graft infiltrating myeloid subsets by flow cytometry. We found that >50% of Ly6Clo macrophages from anti-CD40L mAb-treated Fucci recipients are in G1, while >10% are in S/G2/M phase ( Figure 2D ). We next sorted Ly6Clo macrophages from manti-CD40L mAb-treated Fucci recipients into those in G0, G1, and S/G2/M and tested their immunosuppressive capacity in vitro ( Figure 2E ). The suppression assay demonstrated that the in vitro inhibitory function of graft infiltrating Ly6Clo macrophages is confined to the proliferating S/G2/M subset. This is consistent with our previous collaborative finding, which demonstrated that suppressive monocytic-derived cells from tumor bearing mice are highly proliferative. 26 
| Preventing macrophage cell cycle progression abrogates tolerance
To demonstrate that cell proliferation of Ly6C lo macrophages is necessary for the induction of tolerance, we incorporated simvastatin in a high-density lipoprotein (HDL) nanoparticle to generate simvastatin-HDL (S-HDL) nanoparticles, as we recently described. 27 We cultured bone marrow Ly6C hi monocytes with CSF1 to induce their polarization towards suppressive Ly6C lo monocyte-derived cells ( Figure 3A ).
As expected, addition of S-HDL prevented the polarization of Ly6C 
| DISCUSSION
We demonstrate here that graft-infiltrating neutrophils produce CSF1
that mediates polarization of Ly6C lo suppressive macrophages and promotes transplantation tolerance in the context of costimulatory blockade ( Figure 3D ). This study provides novel understandings about how distinct myeloid cell subsets are interconnected in the tissue and highlights the critical contribution of neutrophils during the induction of indefinite allograft survival. 29 In organ transplantation, the role of neutrophils is commonly associated to antibody mediated and chronic rejection or ischemia reperfusion injury and resolution of inflammation. 30 However, murine neutrophils also release anti-inflammatory cytokines, 31 and recent evidence suggests that neutrophils are able to negatively regulate T cell mediated immune responses. 32 Here, we show that neutrophils favor tolerance by mediating macrophage polarization in the transplanted organ uncovering a previously unrecognized function of neutrophils in the context of organ transplantation.
Data from tumor models also suggest a close relationship be- Therefore, CSF1-dependent macrophage development represents a novel approach for therapeutic intervention either by inhibiting (ie, cancer), or by promoting (ie, transplantation) macrophage polarization. In this respect, the development of monoclonal antibodies that target macrophage polarization through CSF1 receptor signaling has been shown to interfere with macrophage differentiation/proliferation and to prevent tumor progression. 35, 36 We conclude that neutrophils secrete CSF1 that promotes macrophage polarization, progression through the cell cycle, and suppressive function of graft infiltrating macrophages. Future experiments are aimed at elucidating the mechanisms by with anti-CD40L mAb promote "tolerogenic" neutrophils. In this respect, we hypothesize neutrophils scanning for platelets 37 may receive a "tolerogenic" signal following CD40L blockade in activated platelets 38 that may lead to CSF1 production and transplantation tolerance under sterile inflammatory conditions.
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